mRNA 합성 및 제조 시장 : 제품 유형별, 용도별, 치료 분야별, 주요 지역별 : 업계 동향과 세계 예측(-2035년)

mRNA Synthesis and Manufacturing Market by Type of Product (Drug Substances and Drug Products ), Application Area, Therapeutic Area and Key Geographical Regions : Industry Trends and Global Forecasts, Till 2035

US $ 4,799 ￦ 6,943,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 10,126,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 15,335,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 26,042,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 mRNA 합성·제조 시장 규모는 올해 10억 6,000만 달러로 추정되고 있습니다.

최근 수년간 mRNA 기술은 제약 산업에 혁명을 일으켜 다양한 질병과 장애를 예방하고 치료하고 있으며, COVID-19 백신의 성공은 mRNA 백신과 치료제의 길을 열어주었습니다. 지난 수년간 mRNA 기반 치료제/백신과 관련된 170개 이상의 임상시험이 등록되었습니다는 점은 주목할 만합니다. 이러한 플랫폼의 효능을 입증하는 전임상 및 임상 보고가 지난 2년 동안 여러 차례 발표되었습니다. 그 결과, mRNA 생산 능력에 대한 수요가 분명히 증가하고 있습니다. 그러나 mRNA 기반 치료제/백신의 합성 및 제조 공정은 복잡하고 여러 가지 어려움이 있습니다. 이러한 의약품 제조에는 숙련된 인력, 엄격한 제조 프로토콜, 전문적 전문 지식이 필요하며, RNA 기반 의약품 제조와 관련된 이러한 운영 및 기술적 문제로 인해 바이오 제약 산업의 혁신 기업은 위탁 서비스 프로바이더에 대한 의존도를 높이고 있습니다. 이러한 RNA 기반 리드 화합물들이 성숙하고 임상 및 상업화됨에 따라 mRNA 합성 및 제조 서비스 시장은 건강한 성장을 이룰 것으로 예상됩니다.

세계의 mRNA 합성·제조 시장에 대해 조사했으며, 시장의 개요와 제품 유형별, 용도별, 치료 분야별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 제공하고 있습니다.

목차

제1장 서문

제2장 조사 방법

제3장 경제 및 기타 프로젝트 특유의 고려 사항

제4장 개요

제5장 서론

제6장 mRNA 커스텀 합성 서비스 프로바이더 : 시장 구도

• mRNA 커스텀 합성 서비스 프로바이더 : 시장 구도

제7장 mRNA 커스텀 합성 서비스 프로바이더 : 기업 경쟁력 분석

제8장 기업 개요 : mRNA 커스텀 합성 서비스 프로바이더

제9장 mRNA 수탁제조 서비스 프로바이더 : 시장 구도

제10장 mRNA 수탁제조 서비스 프로바이더 : 기업 경쟁력 분석

제11장 기업 개요 : mRNA 수탁제조 서비스 프로바이더

제12장 mRNA 합성 키트 프로바이더 : 시장 구도

제13장 mRNA 합성 키트 : 제품 경쟁력 분석

제14장 기업 개요 : mRNA 합성 키트 프로바이더

• 장의 개요
• Jena Biosciences
• APExBIO
• Thermo Fisher Scientific
• CELLSCRIPT
• New England Biolabs
• Enzynomics

제15장 파트너십과 협업

제16장 파트너 후보 분석

제17장 대형 제약회사 구상

제18장 시장에 대한 영향 분석 : 촉진요인, 억제요인, 기회, 과제

제19장 세계의 mRNA 합성·제조 시장

제20장 mRNA 합성·제조 시장, 제품 유형별

제21장 mRNA 합성·제조 시장, 용도별

제22장 mRNA 합성·제조 시장, 치료 분야별

제23장 mRNA 합성·제조 시장, 주요 지역별

제24장 이그제큐티브 인사이트

제25장 부록 1 : 표 형식 데이터

제26장 부록 2 : 기업 및 조직 리스트

KSA

영문 목차

영문목차

MRNA SYNTHESIS AND MANUFACTURING MARKET: OVERVIEW

As per Roots Analysis, the global mRNA synthesis and manufacturing market is estimated to be worth USD 1.06 billion in the current year.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Product

• Drug Substances (APIs)
• Drug Products (FDFs)

Application Area

• mRNA-based Vaccines
• mRNA-based Therapeutics

Therapeutic Area

• Infectious Diseases
• Oncological Disorders
• Other Disorders

Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Rest of the World

MRNA SYNTHESIS AND MANUFACTURING MARKET: GROWTH AND TRENDS

In recent years, mRNA technology has revolutionized the pharmaceutical industry to prevent and treat a wide array of diseases and disorders. The success of COVID-19 vaccines has paved the path for mRNA vaccines and therapeutics. It is worth highlighting that, in the past few years, more than 170 clinical trials related to mRNA-based therapeutics / vaccines have been registered. Multiple preclinical and clinical reports demonstrating the efficacy of these platforms have been published in the last two years. As a result, there is an evident increase in the demand for mRNA manufacturing capacity. However, the synthesis and manufacturing process of mRNA-based therapeutics / vaccines is complex and associated with several challenges. Production of such drug products requires skilled labor, stringent manufacturing protocols and specialized expertise. Due to such operational and technical challenges associated with the production of RNA-based products, innovators in the biopharmaceutical industry are increasingly relying on contract service providers. In the foreseen future, as more of such RNA-based leads mature and move into the clinic and / or get commercialized, we anticipate the mRNA synthesis and manufacturing services market to witness healthy growth.

MRNA SYNTHESIS AND MANUFACTURING MARKET: KEY INSIGHTS

The report delves into the current state of the mRNA synthesis and manufacturing market and identifies potential growth opportunities within the industry. Some key findings from the report include:

1. The current market landscape features the presence of more than 35 companies that claim to offer services for custom synthesis of mRNA, across the world.

2. Various players offer different types of services for mRNA synthesis, based on the requirements of their clients; majority of the players prefer to use plasmid DNA as a starting material to synthesize mRNA.

3. Over 40 companies currently claim to offer contract manufacturing services for drug substance (mRNA) as well as drug product (mRNA-based vaccines and therapeutics), across various scales of operation.

4. Several firms (encompassing startups as well as well-established companies), with varying resources, have been actively involved in this domain; the majority of these firms have manufacturing facilities in Europe.

5. Presently, more than 95 kits (comprising of different components) are available in the market for the synthesis of customized mRNAs; notably, the majority of these have enzymes for cap modification of the mRNA.

6. mRNA synthesis kits carry out various reactions depending on the number of reagents in the kit; in addition, around 30% of the kits yield over 60 µg of mRNA per reaction.

7. In pursuit of building a competitive edge, stakeholders are actively upgrading their existing capabilities to enhance their respective service offerings and comply with the evolving industry benchmarks.

8. In order to meet the rising demand, drug developers are steadily relying on CMOs for the production of mRNA; this approach not only offers a set of streamlined processes but also greater flexibility.

9. To cater to the rising demand for mRNA synthesis kits, companies are actively undertaking initiatives to integrate advanced features in their respective mRNA synthesis kit portfolios.

10. Both industry and non-industry players have forged strategic partnerships in the mRNA synthesis and manufacturing domain; notably, majority of the deals in this domain were manufacturing agreements.

11. Various mRNA-based therapeutic / vaccine developers across the world are anticipated to forge strategic alliances with mRNA synthesis and manufacturing service providers, to further augment their drug portfolio.

12. Several big pharma players have undertaken a variety of initiatives (partnerships, acquisitions, funding and expansion) for enhancing their mRNA-related portfolio and its therapeutic applicability.

13. Identifying the driving factors (that fuel advancement) as well as barriers (that slow down research progress) helps improve strategic planning and results in efficient operations in mRNA synthesis and manufacturing domain.

14. The opportunity within the mRNA synthesis and manufacturing market is likely to be well distributed across different types of product, application area, therapeutic area and key geographical regions.

MRNA SYNTHESIS AND MANUFACTURING MARKET: KEY SEGMENTS

Drug Substances (APIs) are Likely to Dominate the mRNA Synthesis and Manufacturing Market During the Forecast Period

Based on type of product, the market is segmented into drug substances (APIs) and drug products (FDFs). It is worth highlighting that majority of the current mRNA synthesis and manufacturing market is captured by bulk drug substances (APIs) and this trend is likely to remain the same in near future.

mRNA Therapeutics is the Fastest Growing Segment in the mRNA Synthesis and Manufacturing Market During the Forecast Period

Based on application area, the market is segmented into mRNA-based vaccines and mRNA-based therapeutics. It is worth highlighting that that majority of the current mRNA synthesis and manufacturing market is captured by mRNA vaccines.

Infectious Diseases Segment Accounts for the Largest Share for the mRNA Synthesis and Manufacturing Market

Based on therapeutic area, the market is segmented into infectious diseases, oncological disorders and other disorders. While infectious diseases account for a relatively higher market share, it is worth highlighting that oncological disorders segment is expected to witness substantial market growth in the coming years.

North America Holds the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World. It is worth highlighting that currently, North America captures majority of the mRNA synthesis and manufacturing market, and this trend is unlikely to change in the near future.

Example Players in the mRNA Synthesis and Manufacturing Market

• Aldevron
• Aurigene Pharmaceutical Services
• Biomay
• Curia
• eTheRNA
• Eurogentec
• Genscript
• Merck KGaA
• TriLink BioTechnologies
• Vernal Biosciences
• WuXi Biologics
• APExBIO
• CELLSCRIPT
• Enzynomics
• Jena Bioscience
• New England Biolabs
• Thermo Fisher Scientific

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

• Chief Executive Officer, eTheRNA
• Chief Commercial Officer, tebubio
• Business Development Manager, Canvax
• Team Leader, GC Pharma

MRNA SYNTHESIS AND MANUFACTURING MARKET: RESEARCH COVERAGE

• The report features an in-depth analysis of the mRNA synthesis and manufacturing market, focusing on key market segments, including type of product, application area, therapeutic area and key geographical regions.
• The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting the market growth.
• A comprehensive evaluation of mRNA custom synthesis service providers, considering various parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters (North America, Europe and Asia Pacific), type of services offered (mRNA modification, mRNA purification, scale-up, process development and fill / finish), starting material (plasmid DNA, mRNA sequence and PCR fragments), structural modification (5' modification, 3' modification, ribonucleotide base modification and others), type of purification method (chromatography, electrophoresis, desalting / precipitation and others), application area (vaccine production, therapeutic production and others) and scale of operation (preclinical / research, clinical and commercial). Further, the chapter also features information on the length of the mRNA manufactured and mRNA production capacity of the stakeholders.
• A comprehensive competitive analysis of mRNA custom synthesis service providers (across key geographical regions), examining factors such as supplier strength and service strength.
• Thorough analysis of mRNA contract manufacturing service providers, detailing year of establishment, company size (in terms of number of employees), location of headquarters (North America, Europe and Asia Pacific), location of manufacturing facilities, type of additional services offered (formulation development, analytical testing, process development, mRNA purification, fill / finish, scale-up, regulatory support and others) type of product manufactured (drug substances (APIs) and drug products (FDFs)) and scale of operation (preclinical / research, clinical and commercial).
• A comprehensive competitive analysis of mRNA contract manufacturing service providers (across key geographical regions), examining factors such as supplier strength and service portfolio strength.
• A detailed assessment of the current market landscape of mRNA synthesis kits based on several relevant parameters, such as kit components (enzyme mix, reagents, buffer and others), type of enzyme (capping enzyme and tailing enzyme), type of enzyme mix used (T7 polymerase, SP6 polymerase and T3 polymerase), mRNA component modified (cap, base and tail), number of reactions (5 reactions, 10 reactions, 15 reactions, 16 reactions, 20 reactions, 25 reactions, 48 reactions and 50 reactions), yield per reaction (less than 31µg, 31-60 µg, 61-90 µg and more than 90 µg), reaction run time (less than 61 minutes, 61-120 minutes and more than 120 minutes) and kit price (less than USD 500, USD 501-USD 700, USD 701-USD 900 USD, USD 901-USD 1,200 and more than 1,200 USD). In addition, the chapter provides a detailed analysis of mRNA synthesis kit providers, along with information on their year of establishment, company size (in terms of employees count), location of headquarters and most active players (in terms of number of mRNA synthesis kits offered).
• An insightful analysis of mRNA synthesis kits, based on supplier strength and product strength.
• In-depth profiles of key industry players in mRNA manufacturing market, focusing on company overviews, service portfolio, recent developments and an informed future outlook.
• Detailed profiles of the key mRNA synthesis kit providers, focusing on company overviews and mRNA synthesis kits portfolio.
• An analysis of partnerships established in this sector, since 2019, on the basis of several parameters, such as year of partnership, type of product, type of partner and most active players (in terms of the number of partnerships signed). It also provides for the regional distribution of the companies involved in these agreements.
• A detailed evaluation of over 35 mRNA-based therapeutics / vaccines developers that are most likely to collaborate with mRNA contract manufacturing service providers. This analysis considers various relevant parameters, including developer strength (in terms of company's experience), company size, (in terms of number of employees), pipeline strength (based on the number of mRNA-based drugs in pipeline), highest phase of development, therapeutic area, route of administration and type of candidate being developed.
• Assessment of the various mRNA-focused initiatives undertaken by big pharma players, based on several relevant parameters, such as number of initiatives, year of initiative, purpose of initiative, type of initiative and therapeutic area.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What kind of partnership models are commonly adopted by industry stakeholders?
• What are the factors that are likely to influence the evolution of this market?
• What is current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 10% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. mRNA Synthesis and mRNA Manufacturing Market
• 1.2. Market Share Insights
  • 1.2.1. Market Segmentation Overview
• 1.3. Key Market Insights
• 1.4. Report Coverage
• 1.5. Key Questions Answered
• 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
• 2.3. Project Methodology
• 2.4. Forecast Methodology
• 2.5. Robust Quality Control
• 2.6. Key Market Segmentations
• 2.7. Key Considerations
  • 2.7.1. Demographics
  • 2.7.2. Economic Factors
  • 2.7.3. Government Regulations
  • 2.7.4. Supply Chain
  • 2.7.5. COVID Impact / Related Factors
  • 2.7.6. Market Access
  • 2.7.7. Healthcare Policies
  • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

• 3.1. Chapter Overview
• 3.2. Market Dynamics
  • 3.2.1. Time Period
    • 3.2.1.1. Historical Trends
    • 3.2.1.2. Current and Forecasted Estimates
  • 3.2.2. Currency Coverage
    • 3.2.2.1. Overview of Major Currencies Affecting the Market
    • 3.2.2.2. Impact of Currency Fluctuations on the Industry
  • 3.2.3. Foreign Exchange Impact
    • 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
    • 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
  • 3.2.4. Recession
    • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
    • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
  • 3.2.5. Inflation
    • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

• 5.1. Overview of mRNA
• 5.2. Structure of mRNA
• 5.3. Evolution of mRNA Vaccines
• 5.4. Steps involved in mRNA Synthesis
  • 5.4.1. Chemical Synthesis of mRNA
  • 5.4.2. In vitro Synthesis of mRNA
• 5.5. Applications of Chemical/ in vitro Synthesized mRNA
• 5.6. Challenges Associated with mRNA Synthesis
• 5.7. mRNA Contract Manufacturing
  • 5.7.1. Commonly Outsourced mRNA Manufacturing Operations
  • 5.7.2. Advantages of Outsourcing Manufacturing Operations

6. mRNA CUSTOM SYNTHESIS SERVICE PROVIDERS: MARKET LANDSCAPE

• 6.1. mRNA Custom Synthesis Service Providers: Market Landscape
  • 6.1.1. Analysis by Year of Establishment
  • 6.1.2. Analysis by Company Size
  • 6.1.3. Analysis by Location of Headquarters
  • 6.1.4. Analysis by Type of Service Offered
  • 6.1.5. Analysis by Starting Material
  • 6.1.6. Analysis by Structural Modification
  • 6.1.7. Analysis by Type of Purification Method
  • 6.1.8. Analysis by Application Area
  • 6.1.9. Analysis by Scale of Operation
  • 6.1.10. mRNA Custom Synthesis Service Providers: Information on Length (Base Pair) of mRNA Synthesized
  • 6.1.11. mRNA Custom Synthesis Service Providers: Information on mRNA Production Capacity

7. mRNA CUSTOM SYNTHESIS SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS

• 7.1. Chapter Overview
• 7.2. Assumptions and Methodology
• 7.3. Scoring Criteria
• 7.4. mRNA Custom Synthesis Service Providers: Company Competitiveness Analysis
  • 7.4.1. mRNA Custom Synthesis Service Providers based in North America
  • 7.4.2. mRNA Custom Synthesis Service Providers based in Europe
  • 7.4.3. mRNA Custom Synthesis Service Providers based in Asia-Pacific

8. COMPANY PROFILES: mRNA CUSTOM SYNTHESIS SERVICE PROVIDERS

• 8.1. Chapter Overview
• 8.2. Detailed Company Profiles of Leading Service Providers
  • 8.2.1. Aldevron
    • 8.2.1.1. Company Overview
    • 8.2.1.2. mRNA Custom Synthesis Service Portfolio
    • 8.2.1.3. Recent Developments and Future Outlook
  • 8.2.2. TriLink BioTechnologies
    • 8.2.2.1. Company Overview
    • 8.2.2.2. mRNA Custom Synthesis Service Portfolio
    • 8.2.2.3. Recent Developments and Future Outlook
  • 8.2.3. eTheRNA
    • 8.2.3.1. Company Overview
    • 8.2.3.2. mRNA Custom Synthesis Service Portfolio
    • 8.2.3.3. Recent Developments and Future Outlook
• 8.3. Short Profiles of Other Prominent Custom Service Providers
  • 8.3.1. Biomay
    • 8.3.1.1. Company Overview
    • 8.3.1.2. mRNA Custom Synthesis Service Portfolio
  • 8.3.2. Genscript
    • 8.3.2.1. Company Overview
    • 8.3.2.2. mRNA Custom Synthesis Service Portfolio
  • 8.3.3. Aurigene Pharmaceutical Services
    • 8.3.3.1. Company Overview
    • 8.3.3.2. mRNA Custom Synthesis Service Portfolio

9. mRNA CONTRACT MANUFACTURING SERVICE PROVIDERS: MARKET LANDSCAPE

• 9.1. mRNA Contract Manufacturing Service Providers: Market Landscape
  • 9.1.1. Analysis by Year of Establishment
  • 9.1.2. Analysis by Company Size
  • 9.1.3. Analysis by Location of Headquarters (Region)
  • 9.1.4. Analysis by Location of Headquarters (Country)
  • 9.1.5. Analysis by Location of Manufacturing Facility
  • 9.1.6. Analysis by Type of Additional Services
  • 9.1.7. Analysis by Type of Product Manufactured
  • 9.1.8. Analysis by Scale of Operation

10. mRNA CONTRACT MANUFACTURING SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS

• 10.1. Chapter Overview
• 10.2. Assumptions and Methodology
• 10.3. Scoring Criteria
• 10.4. mRNA Contract Manufacturing Service Providers: Company Competitiveness Analysis
  • 10.4.1. mRNA Contract Manufacturing Service Providers based in North America
  • 10.4.2. mRNA Contract Manufacturing Service Providers based in Europe
  • 10.4.3. mRNA Contract Manufacturing Service Providers based in Asia-Pacific

11. COMPANY PROFILES: mRNA CONTRACT MANUFACTURING SERVICE PROVIDERS

• 11.1. Chapter Overview
• 11.2. Detailed Company Profiles of Leading Service Providers
  • 11.2.1. Eurogentac
    • 11.2.1.1. Company Overview
    • 11.2.1.2. mRNA Contract Manufacturing Services Portfolio
    • 11.2.1.3. Recent Developments and Future Outlook
  • 11.2.2. WuXi Biologics
    • 11.2.2.1. Company Overview
    • 11.2.2.2. mRNA Contract Manufacturing Services Portfolio
    • 11.2.2.3. Recent Developments and Future Outlook
  • 11.2.3. Merck
    • 11.2.3.1. Company Overview
    • 11.2.3.2. mRNA Contract Manufacturing Services Portfolio
    • 11.2.3.3. Recent Developments and Future Outlook
• 11.3. Short Profiles of Other Prominent Service Providers
  • 11.3.1. ST Pharm
    • 11.3.1.1. Company Overview
    • 11.3.1.2. mRNA Contract Manufacturing Services Portfolio
  • 11.3.2. Vernal Biosciences
    • 11.3.2.1. Company Overview
    • 11.3.2.2. mRNA Contract Manufacturing Services Portfolio
  • 11.3.3. Curia
    • 11.3.3.1. Company Overview
    • 11.3.3.2. mRNA Contract Manufacturing Services Portfolio

12. mRNA SYNTHESIS KIT PROVIDERS: MARKET LANDSCAPE

• 12.1. mRNA Synthesis Kits: Market Landscape
  • 12.1.1. Analysis by Kit Components
  • 12.1.2. Analysis by Type of Enzyme
  • 12.1.3. Analysis by Type of Enzyme Mix Used
  • 12.1.4. Analysis by mRNA Component Modified
  • 12.1.5. Analysis by Number of Reaction
  • 12.1.6. Analysis by Yield per Reaction
  • 12.1.7. Analysis by Reaction Run-time
  • 12.1.8. Analysis by Kit Price
  • 12.1.9. Most Active Players: Analysis by Number of Kits Offered
• 12.2. mRNA Synthesis Kits: Providers Landscape
  • 12.2.1. Analysis by Year of Establishment
  • 12.2.2. Analysis by Company Size
  • 12.2.3. Analysis by Location of Headquarters

13. mRNA SYNTHESIS KITS: PRODUCT COMPETITIVENESS ANALYSIS

• 13.1. Chapter Overview
• 13.2. Assumptions and Methodology
• 13.3. Scoring Criteria
• 13.4. mRNA Synthesis Kits: Product Competitiveness Analysis

14. COMPANY PROFILES: mRNA SYNTHESIS KIT PROVIDERS

• 14.1. Chapter Overview
• 14.2. Jena Biosciences
  • 14.2.1. Company Overview
  • 14.2.2. mRNA Synthesis Kits Portfolio
• 14.3. APExBIO
  • 14.3.1. Company Overview
  • 14.3.2. mRNA Synthesis Kits Portfolio
• 14.4. Thermo Fisher Scientific
  • 14.4.1. Company Overview
  • 14.4.2. mRNA Synthesis Kits Portfolio
• 14.5. CELLSCRIPT
  • 14.5.1. Company Overview
  • 14.5.2. mRNA Synthesis Kits Portfolio
• 14.6. New England Biolabs
  • 14.6.1. Company Overview
  • 14.6.2. mRNA Synthesis Kits Portfolio
• 14.7. Enzynomics
  • 14.7.1. Company Overview
  • 14.7.2. mRNA Synthesis Kits Portfolio

15. PARTNERSHIPS AND COLLABORATIONS

• 15.1. Partnership Models
• 15.2. mRNA Synthesis and Manufacturing: Partnerships and Collaborations
  • 15.1.1. Analysis by Year of Partnership
  • 15.1.2. Analysis by Type of Partnership
  • 15.1.3. Analysis by Year and Type of Partnership
  • 15.1.4. Analysis by Type of Product
  • 15.1.5. Analysis by Type of Partner
  • 15.1.6. Most Active Players: Analysis by Number of Partnerships
  • 15.1.7. Analysis by Geography
    • 15.1.7.1. Intracontinental and Intercontinental Deals
    • 15.1.7.2. Local and International Deals

16. LIKELY PARTNER ANALYSIS

• 16.1. Methodology and Key Parameters
• 16.2. Scoring Criteria
• 16.3. mRNA Drug Developers: Likely Partners based in North America
  • 16.3.1. mRNA Drug Developers: Most Likely Partners based in North America
• 16.4. mRNA Drug Developers: Likely Partners based in Europe
  • 16.4.1. mRNA Drug Developers: Most Likely Partners based in Europe
• 16.5. mRNA Drug Developers: Likely Partners based in Asia-Pacific and Rest of the World
  • 16.5.1. mRNA Drug Developers: Most Likely Partners based in Asia-Pacific and Rest of the World

17. BIG PHARMA INITIATIVES

• 17.1. Analysis Methodology
• 17.2. Scoring Criteria
• 17.3. Big Pharma Players: mRNA- focused Initiatives
• 17.4. Competitive Benchmarking of Big Pharma Players

18. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

• 18.1. Chapter Overview
• 18.2. Market Drivers
• 18.3. Market Restraints
• 18.4. Market Opportunities
• 18.5. Market Challenges

19. GLOBAL mRNA SYNTHESIS AND MANUFACTURING MARKET

• 19.1. Chapter Overview
• 19.2. Key Assumptions and Forecast Methodology
• 19.3. Global mRNA Synthesis and Manufacturing Market, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)
  • 19.3.1. Scenario Analysis
• 19.4. Key Market Segmentations

20. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY TYPE OF PRODUCT

• 20.1. Chapter Overview
• 20.2. Key Assumptions and Forecast Methodology
• 20.3. mRNA Synthesis and Manufacturing Market: Distribution by Type of Product, 2021, 2024 and 2035
  • 20.3.1. mRNA Synthesis and Manufacturing: Market for Drug Substances (APIs), till 2035 (USD Billion)
  • 20.3.2. mRNA Synthesis and Manufacturing Market for Drug Products (FDFs), till 2035 (USD Billion)

21. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY APPLICATION AREA

• 21.1. Chapter Overview
• 21.2. Key Assumptions and Forecast Methodology
• 21.3. mRNA Synthesis and Manufacturing Market: Distribution by Application Area, 2021, 2024 and 2035
  • 21.3.1. mRNA Synthesis and Manufacturing Market for mRNA-based Vaccines, till 2035 (USD Billion)
  • 21.3.2. mRNA Synthesis and Manufacturing Market for mRNA-based Therapeutics, till 2035 (USD Billion)

22. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY THERAPEUTIC AREA

• 22.1. Chapter Overview
• 22.2. Key Assumptions and Forecast Methodology
• 22.3. mRNA Synthesis and Manufacturing Market: Distribution by Therapeutic Area, 2021, 2023 and 2035
  • 22.3.1. mRNA Synthesis and Manufacturing Market for Infectious Diseases, till 2035 (USD Billion)
  • 22.3.2. mRNA Synthesis and Manufacturing Market for Oncological Disorders, till 2035 (USD Billion)
  • 22.3.3 mRNA Synthesis and Manufacturing Market for Other Disorders, till 2035 (USD Billion)

23. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS

• 23.1. Chapter Overview
• 23.2. Key Assumptions and Forecast Methodology
• 23.3. mRNA Synthesis and Manufacturing Market: Distribution by Key Geographical Regions, 2021, 2024 and 2035
  • 23.3.1 mRNA Synthesis and Manufacturing Market in North America, till 2035 (USD Billion)
  • 23.3.2. mRNA Synthesis and Manufacturing Market in Europe, till 2035 (USD Billion)
  • 23.3.3. mRNA Synthesis and Manufacturing Market in Asia-Pacific, till 2035 (USD Billion)
  • 23.3.4. mRNA Synthesis and Manufacturing Market in Latin America, till 2035 (USD Billion)
  • 23.3.5. mRNA Synthesis and Manufacturing Market in Middle East and North Africa, till 2035 (USD Billion)
  • 23.3.6. mRNA Synthesis and Manufacturing Market in Rest of the World, till 2035, USD Billion

24. EXECUTIVE INSIGHTS

• 24.1. Chapter Overview
• 24.2. Canvax
  • 24.2.1. Company Snapshot
  • 24.2.2. Interview Transcript: Bernardo Jose Gomez Fernandez, Business Development Manager
• 24.3. GC Pharma
  • 24.3.1. Company Snapshot
  • 24.3.2. Interview Transcript: Jaehoon Moon, Team Leader
• 24.4 Tebubio
  • 24.4.1. Company Snapshot
  • 24.4.2. Interview Transcript: Jean-Francois, Chief Commercial Officer

25. APPENDIX 1: TABULATED DATA

26. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

관련자료